
Home Infusion Therapy Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.

Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The global home infusion therapy market size was valued at USD 36.6 billion in 2024. The market is expected to reach from USD 40.7 billion in 2025 to USD 89.8 billion in 2034, growing at a CAGR of 9.2% during the forecast period, according to the latest report published by Global Market Insights Inc. The high market growth is attributed to the increasing prevalence of chronic diseases, shift toward cost-effective healthcare delivery, ongoing advancements in infusion devices and technology, and growing geriatric population, among other contributing factors.
To get key market trends
Home infusion therapy is the process of delivering drugs or nutrients directly into a patient's blood via intravenous (IV) or subcutaneous methods at home. This therapy is generally associated with the use of antibiotics, chemotherapy, pain alleviation, and parenteral nutrition for a prolonged period.
Leading players in the home infusion therapy market include B. BRAUN, Baxter, Becton Dickinson and Company, FRESENIUS KABI, and ICU Medical. These companies maintain their competitive edge through continuous product innovation, global market presence, and significant investments in research and development.
The market has increased from USD 25.9 billion in 2021 and reached USD 32.8 billion in 2023, with the historic growth rate of 12.6%. The market growth was driven by the growing shift toward cost-effective treatment alternatives, expanding reimbursement coverage for home infusion services, rising hospital congestion encouraging outpatient care, and improved safety and portability of infusion pumps.
Moreover, the increasing incidence of chronic conditions such as cancer, diabetes, gastrointestinal disorders, immune deficiencies, and heart failure is a major driver of market growth. For instance, according to the World Health Organization (WHO), cancer accounted for nearly 10 million deaths globally in 2021, while the International Diabetes Federation (IDF) reported that approximately 589 million adults were living with diabetes in 2021 a number projected to rise to 853 million by 2050.
These patients often require long-term intravenous (IV) therapies such as antibiotics, chemotherapy, and parenteral nutrition. Home infusion therapy enables safe and continuous treatment outside hospital settings, reducing the burden on healthcare facilities while improving patient comfort and convenience.
Furthermore, the development of portable, user-friendly infusion pumps and smart infusion systems is enhancing therapy safety and accuracy at home. Remote monitoring features also enable real-time communication between patients and healthcare providers.
| Key Takeaway | Details |
|---|---|
| Market Size & Growth | |
| Base Year | 2024 |
| Market Size in 2024 | USD 36.6 Billion |
| Market Size in 2025 | USD 40.7 Billion |
| Forecast Period 2025 – 2034 CAGR | 9.2% |
| Market Size in 2034 | USD 89.8 Billion |
| Key Market Trends | |
| Drivers | Impact |
| Growing hospital acquired infections | The rising risk of HAIs is accelerating the shift of patients from hospitals to safer home-based treatment alternatives, significantly boosting demand for home infusion therapy. |
| Rising prevalence of chronic diseases | Increasing cases of cancer, diabetes, immune disorders, and cardiovascular diseases are driving long-term infusion needs, creating consistent demand for home-based therapy solutions. |
| Advancements in technology | Smart infusion pumps, remote monitoring systems, and user-friendly infusion devices are enhancing safety and ease of use, encouraging broader adoption of home infusion therapy. |
| Growing geriatric population | The rising elderly population requiring long-term care for chronic illnesses is increasing demand for convenient and cost-effective home-based infusion services. |
| Increasing preference towards at-home healthcare solutions | Patients and healthcare providers are favoring home care due to reduced treatment costs and improved comfort, strengthening market growth. |
| Pitfalls & Challenges | Impact |
| Dearth of reimbursement | Limited insurance coverage and inconsistent reimbursement policies across regions are restricting patient access to home infusion services, hindering market expansion. |
| Safety concerns and risk of failure associated with home infusion devices | Safety concerns and risk of failure associated with home infusion devices |
| Opportunities: | Impact |
| Increasing adoption of intravenous immunoglobulin (IVIG) therapy | Rising use of IVIG for autoimmune and immunodeficiency disorders is expected to create strong future demand for home infusion services, as patients increasingly opt for long-term treatment outside hospitals. |
| Growing demand for personalized care | The shift toward customized treatment plans and patient-centric home healthcare models will drive innovation in infusion delivery and expand market opportunities for tailored therapy solutions. |
| Market Leaders (2024) | |
| Market Leaders |
~18% Market Share |
| Top Players |
Collective market share in 2024 is ~65% |
| Competitive Edge |
|
| Regional Insights | |
| Largest Market | North America |
| Fastest growing market | Asia Pacific |
| Emerging countries | India, China, Brazil, Mexico, South Africa |
| Future outlook |
|
The market is growing considerably with the growing use of telehealth and remote monitoring, rapid adoption of specialty infusion services, rising demand for ambulatory infusion centers, and technological evolution of infusion pumps, among other factors collectively driving industry growth.

The global market was valued at USD 25.9 billion in 2021. The market size reached USD 32.8 billion in 2023, from USD 29.4 billion in 2022.
Based on the product, the market is segmented into infusion pumps, needleless connectors, intravenous sets, and IV cannulas. The infusion pumps segment has asserted its dominance in the market by securing a significant market share of 52.7% in 2024 owing to their widespread use in home care, advanced safety features, and rising demand for chronic disease management. The segment is expected to exceed USD 46.1 billion by 2034, growing at a CAGR of 8.9% during the forecast period.
On the other hand, the needleless connectors segment is expected to grow with a CAGR of 9.8%. The growth of this segment is driven by increasing emphasis on infection prevention, rising need to reduce needlestick injuries among healthcare providers, and growing adoption of safe intravenous access devices in home care settings.
Based on application, the home infusion therapy market is segmented into anti-infective, enteral nutrition, specialty pharmaceuticals, parenteral nutrition, hydration therapy, chemotherapy, and other applications. The anti-infective segment dominated the market in 2024, accounting for USD 10.3 billion and is anticipated to grow at a CAGR of 8.8% during the forecast period.

Based on distribution channel, the home infusion therapy market is classified into direct sales and indirect sales. The direct sales segment dominated the market with a revenue share of 71.1% in 2024 and is expected to reach USD 62.7 billion within the forecast period.

North America dominated the global market with the highest market share of 44.2% in 2024.
Europe market accounted for USD 11.4 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
The Asia Pacific market is anticipated to grow at the highest CAGR of 10.7% during the analysis timeframe.
The Latin America market is experiencing robust growth over the analysis timeframe.
The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.
Key players in the market include B. Braun, Baxter, Becton Dickinson and Company, Fresenius Kabi, and ICU Medical, collectively accounting for around ~65% of the total market share. The market is moderately competitive, characterized by the presence of global medical device manufacturers as well as specialized home infusion service providers.
Large multinational companies dominate the market through extensive product portfolios covering infusion pumps, IV sets, and parenteral nutrition solutions. Regional service providers, on the other hand, focus on patient-centric offerings, including home nursing support and therapy coordination, to strengthen their market position.
Competition is driven by innovation, service integration, and long-term partnerships with healthcare providers and payers. Companies are increasingly adopting digital health tools such as connected infusion pumps and remote monitoring platforms to differentiate their offerings.
Strategic mergers, acquisitions, and collaborations are common as market leaders aim to expand their service networks and geographic presence. Increasing focus on value-based healthcare delivery is also pushing players to enhance safety, efficiency, and outcomes in home-based infusion therapy.
A few of the prominent players operating in the home infusion therapy industry include:
Offers a comprehensive portfolio of infusion pumps, IV administration sets, and safety catheters designed specifically for home-based therapy. Strong focus on safety infusion technologies and integrated therapy services through B. Braun HomeCare.
Leader in parenteral nutrition and IV solutions, widely used for long-term home care patients. Strong global distribution and service infrastructure support reliable product availability for chronic infusion therapies.
Specializes in advanced IV access devices, catheters, and needleless connectors that enhance safety in home infusion settings. Known for infection prevention technologies that reduce catheter-related bloodstream infections in home care patients.
Market, By Product
Market, By Application
Market, By Distribution Channel
The above information is provided for the following regions and countries:
Key players include B. Braun, Baxter, Becton Dickinson and Company, Fresenius Kabi, ICU Medical, AMSINO, Contec Medical Systems, Erenler Medikal, Halyard Health (Avanos), JMS, Mindray, Moog, Nipro, Polymed, and Terumo.
The Asia Pacific region is projected to grow at the fastest CAGR of 10.7% through 2034, driven by rapid healthcare infrastructure development, growing medical tourism, and government support for decentralized healthcare delivery.
The direct sales segment led the market with a 71.1% share (USD 26 billion) in 2024, as hospitals and home healthcare agencies preferred direct procurement from manufacturers for product authenticity, technical support, and competitive pricing.
North America dominated the market with a 44.2% share (USD 16.2 billion) in 2024, supported by high chronic disease prevalence, favorable reimbursement policies, and widespread adoption of advanced homecare technologies.
The anti-infective therapy segment dominated the market with USD 10.3 billion revenue in 2024, driven by rising incidences of infections such as osteomyelitis and endocarditis requiring prolonged IV antibiotic treatments at home.
The infusion pumps segment held the largest share of 52.7% (USD 19.3 billion) in 2024, owing to their accuracy, safety features such as dose-error reduction systems (DERS), and essential role in long-term chronic disease management at home.
The market is projected to reach USD 40.7 billion in 2025, supported by growing demand for specialty infusion therapies and technological advancements in portable and connected infusion pumps.
The market is expected to reach USD 89.8 billion by 2034, growing at a CAGR of 9.2%, fueled by the adoption of smart infusion devices, expansion of home healthcare infrastructure, and integration of telehealth and remote monitoring technologies.
The market size was USD 36.6 billion in 2024, driven by the increasing prevalence of chronic diseases, growing geriatric population, and rising preference for cost-effective home-based healthcare solutions.


